NCT02452385暂停1 期
Phase 1 Study of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
AnewPharma6 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 发起方
- 入组人数
- 56
- 试验地点
- 6
- 主要终点
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD.
详细描述
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CM082 tablets in Chinese Patients With wAMD. Patients will receive one of four doses for up to four weeks. Single/multiple dose pharmacokinetics in these patients will be studied. At the end of four weeks, investigator will evaluate safety and tolerability and decide whether to continue treatment for a total of six months to further evaluate safety and preliminary efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active choroidal neovascularization (CNV) associated with AMD, as evidenced on fluorescein angiography (FA) and OCT.
- •Patients with either no previous anti-VEGF therapy or prior anti-VEGF therapy with evidence of response to treatment and the need for additional treatment.
- •Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA 20/40 to 20/320 in the study eye(s).
- •Adequate bone marrow, hepatic, and renal functions.
- •Willing and able to provide written informed consent, comply with the investigational study protocol and return for all study visits.
排除标准
- •Patients with Polypoidal Choroidal Vasculopathy (PCV) as evidenced on Indocyanine Green Angiography (ICG).
- •Previous treatment with photodynamic therapy (PDT), external beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy.
- •CNV due to causes other than AMD, including ocular histoplasmosis syndrome, angioid streaks, multifocal choroiditis, choroidal rupture, or pathologic myopia.
- •Geographic atrophy involving the foveal center in the study eye.
- •Any retinal vascular disease or retinal degeneration other than AMD in the study eye.
- •Any significant disease in the study eye that could compromise best-corrected visual acuity.
- •Cataract surgery in the study eye within three months of screening.
- •Trabeculectomy or aqueous shunt or valve in the study eye.
- •Use of any investigational agent or participation in any other clinical trial of an investigational agent or investigational therapy within thirty (30) days of baseline.
- •Females of child bearing potential that are pregnant or not using medically acceptable contraception; males unwilling to take adequate contraceptive measures.
- •Serious allergy to or prior significant adverse reaction to fluorescein.
- •Undiagnosed acute illness first observed during screening or between screening and baseline, or severe concurrent medical conditions that, in the investigators judgment, represent a safety concern.
- •Severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute coronary syndrome, myocardial infarction or coronary artery revascularization, or arterial thrombosis within 12 months of start of study drug, inadequately controlled hypertension, or ventricular tachyarrhythmias requiring ongoing treatment.
- •QTc ≥450 msec or subjects with a history of risk factors for Torsades de Pointes.
- •Stroke or transient ischemic attack within 12 months of trial entry.
- •Clinically significant impaired renal or hepatic function.
- •Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of CM
- •Serious active infection, other serious medical condition or any other condition that would impair the ability of the subject to administer the investigational drug or to adhere to the study protocol requirements.
- •Presence of any condition which, in the judgment of the investigator, would prevent the subject from completing the study.
- •Need to take any medicine that is a strong inhibitor or inducer of CYP3A4.
研究组 & 干预措施
CM082 tablet
Experimental
Escalating dose of CM082 tablet starting at 25mg once a day
干预措施: CM082 tablet (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
时间窗: six months
Incidence of the adverse event after treatment
次要结局
- Change in best corrected visual acuity (BCVA) (in number of letters)(six months)
- Area under the plasma concentration versus time curve (AUC) of CM082(four weeks)
- Change in Central Retinal Thickness(six months)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsAdvanced Malignant Solid TumorsNCT03792958AnewPharma19
Unknown
1 期
Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric CancerAdvanced Gastric CancerNCT03286244AnewPharma21
Unknown
1 期
Study of the Combination of CM082 With Everolimus in Patients With mRCCRenal Cell Carcinoma RecurrentNCT02577458AnewPharma18
已完成
1 期
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid TumorsHER2-Positive Solid TumorsNCT04501770Wuhan YZY Biopharma Co., Ltd.34
已完成
1 期
Study to Assess PDM608 in Healthy Adult SubjectsParkinson DiseaseNCT05950906Calibr, a division of Scripps Research64